Rest left ventricular function and contractile reserve by dobutamine stress echocardiography in peripartum cardiomyopathy

Barbosa, Márcia M.; Freire, Cláudia Maria Vilas; Nascimento, Bruno Ramos; Rochitte, Carlos Eduardo; Silva, Marly C; Siqueira, Maria Helena Albernaz; Nunes, Maria Carmo P.

doi:10.1016/j.repc.2012.02.002

Cited by 16 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a series of seven patients, the presence of inotropic contractile reserve-defined as the improvement of wall motion score in ≥2 segments-was a better predictor than resting LVEF of LV functional recovery during follow-up (49). Conversely, in another cohort of nine patients, resting LVEF was the sole predictor of LV functional recovery at follow-up (50). Small sample sizes, different DSE protocols, and clinical characteristics of the two patient populations may explain the conflicting results.…”

Section: Echocardiographymentioning

confidence: 89%

The Role of Multimodality Cardiovascular Imaging in Peripartum Cardiomyopathy

Ricci

Innocentiis

Verrengia

et al. 2020

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Ricci et al. Multimodality Imaging in Peripartum Cardiomyopathy KEY POINTS-Peripartum cardiomyopathy is a rare but potentially fatal disease requiring prompt identification and treatment. -Cardiac imaging plays a pivotal role for the diagnosis, risk stratification, and follow-up of peripartum cardiomyopathy and related complications. -Cardiovascular magnetic resonance is a high-throughput imaging modality providing relevant information for clinical decision-making and understanding of the pathophysiology underlying peripartum cardiomyopathy.

show abstract

Section: Echocardiographymentioning

confidence: 89%

The Role of Multimodality Cardiovascular Imaging in Peripartum Cardiomyopathy

Ricci

Innocentiis

Verrengia

et al. 2020

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Dobutamine is a synthetic catecholamine widely used in the management of stress, cardiogenic shock and HF [17,18]. Dobutamine primarily stimulates β 1 -adrenergic receptors, and partly the β 2 -adrenergic receptors, in the heart to produce dose-dependent ionotropic and chronotropic effects, and is used for maintenance of cardiac functions in severe heart failure [19,20]. Intravenously administered recombinant human brain natriuretic peptide (rhBNP) is the recombinant formulation of human Btype natriuretic peptide, a 32 amino acid endogenous neurohormonal released from the atria and cardiac ventricles in cardiac overload, wall stress and hypertrophy [21,22].…”

Section: Introductionmentioning

confidence: 99%

Retracted: rhBNP therapy can improve clinical outcomes and reduce in‐hospital mortality compared with dobutamine in heart failure patients: a meta‐analysis

Deng

Long

2015

Brit J Clinical Pharma

View full text Add to dashboard Cite

Aims A meta‐analysis was performed to compare the therapeutic outcomes in patients treated for heart failure (HF) with recombinant human brain natriuretic peptide (rhBNP) and dobutamine. Methods PubMed, Embase and the Chinese Biomedical Database were exhaustively searched to identify studies relevant to this meta‐analysis. Eight cohort studies were found suitable for inclusion. Data regarding trial validity, methodological processes and clinical outcomes were extracted. Results Patients treated with rhBNP showed statistically significant reduction of in‐hospital mortality and re‐admission rates compared with the dobutamine treated patient group (both P < 0.05). Further, the rhBNP treated patient group showed higher survival outcomes, compared with dobutamine treated patients, when the post‐treatment follow‐up period was longer than 6 months (P < 0.05). Stratified analysis based on ethnicity showed a dramatic decrease of in‐hospital mortality among mixed race HF patients receiving rhBNP treatment (P < 0.05), but such decreases were not statistically significant in Asian and Caucasian populations (both P > 0.05). On the other hand, re‐admission rates were significantly lower in rhBNP treated Caucasian and mixed race populations (both P < 0.05). Notably, in rhBNP treated group, dose levels of 0.015 and 0.03 incrementally lowered the re‐admission rates, displaying dose effect, and the re‐admission rates at both rhBNP doses were significantly lower than the dobutamine treated group (both P < 0.05). Conclusions Our meta‐analysis results suggested that rhBNP therapy is associated with lower in‐hospital mortality and re‐admission rates in HF patients compared to the dobutamine regimen. Nevertheless, large scale prospective, randomized trials are necessary to confirm these findings.

show abstract

“…Currently, no evidence based strategies are available for stratifying risk in women with recovered left ventricular function who wish to conceive again, although some researchers have advocated for the assessment of contractile reserve with stress echocardiography 154155. Women with a history of PPCM should be counseled about the risks of subsequent pregnancy and should be followed closely throughout pregnancy and until six months postpartum with frequent clinical examinations and serial echocardiograms 116151.…”

Section: Counseling Women With Peripartum Cardiomyopathymentioning

confidence: 99%

Peripartum cardiomyopathy

Honigberg

Givertz

2019

BMJ

145

154

View full text Add to dashboard Cite

Peripartum cardiomyopathy (PPCM) is a rare, often dilated, cardiomyopathy with systolic dysfunction that presents in late pregnancy or, more commonly, the early postpartum period. Although the condition is prevalent worldwide, women with black ancestry seem to be at greatest risk, and the condition has a particularly high incidence in Nigeria and Haiti. Other risk factors include pre-eclampsia, advanced maternal age, and multiple gestation pregnancy. Although the complete pathophysiology of peripartum cardiomyopathy remains unclear, research over the past decade suggests the importance of vasculo-hormonal pathways in women with underlying susceptibility. At least some women with the condition harbor an underlying sarcomere gene mutation. More than half of affected women recover systolic function, although some are left with a chronic cardiomyopathy, and a minority requires mechanical support or cardiac transplantation (or both). Other potential complications include thromboembolism and arrhythmia. Currently, management entails standard treatments for heart failure with reduced ejection fraction, with attention to minimizing potential adverse effects on the fetus in women who are still pregnant. Bromocriptine is one potential disease specific treatment under investigation. In this review, we summarize the current literature on peripartum cardiomyopathy, as well as gaps in the understanding of this condition and future research directions.

show abstract

Rest left ventricular function and contractile reserve by dobutamine stress echocardiography in peripartum cardiomyopathy

Cited by 16 publications

References 27 publications

The Role of Multimodality Cardiovascular Imaging in Peripartum Cardiomyopathy

The Role of Multimodality Cardiovascular Imaging in Peripartum Cardiomyopathy

Retracted: rhBNP therapy can improve clinical outcomes and reduce in‐hospital mortality compared with dobutamine in heart failure patients: a meta‐analysis

Peripartum cardiomyopathy

Contact Info

Product

Resources

About